The global Human Prothrombin Complex market size was valued at US$ 2025 million in 2024 and is forecast to a readjusted size of USD 4309 million by 2031 with a CAGR of 11.5% during review period.
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.
Global Human Prothrombin Complex key players include Octapharma, Shire, CSL, etc. Global top three manufacturers hold a share over 75%.
North America is the largest market, with a share about 45%, followed by Europe, and Asia-Pacific, both have a share about 45 percent.
In terms of product, 500 IU/Vial is the largest segment, with a share over 50%. And in terms of application, the largest application is Hemophilia B, followed by Vitamin K Deficiency, etc.
This report is a detailed and comprehensive analysis for global Human Prothrombin Complex market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Prothrombin Complex market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (M USD/Unit), 2020-2031
Global Human Prothrombin Complex market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (M USD/Unit), 2020-2031
Global Human Prothrombin Complex market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (M USD/Unit), 2020-2031
Global Human Prothrombin Complex market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (M USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Prothrombin Complex
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Prothrombin Complex market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, CSL, Grifols, Octapharma, Hualan Biological, Meheco Xinxing Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Human Prothrombin Complex market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
500 IU/Vial
600 IU/Vial
1000 IU/Vial
Others
麻豆原创 segment by Application
Hemophilia B
Vitamin K Deficiency
Others
Major players covered
Takeda
CSL
Grifols
Octapharma
Hualan Biological
Meheco Xinxing Pharma
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Prothrombin Complex product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Prothrombin Complex, with price, sales quantity, revenue, and global market share of Human Prothrombin Complex from 2020 to 2025.
Chapter 3, the Human Prothrombin Complex competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Prothrombin Complex breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Human Prothrombin Complex market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Prothrombin Complex.
Chapter 14 and 15, to describe Human Prothrombin Complex sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Human Prothrombin Complex Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 500 IU/Vial
1.3.3 600 IU/Vial
1.3.4 1000 IU/Vial
1.3.5 Others
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Human Prothrombin Complex Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hemophilia B
1.4.3 Vitamin K Deficiency
1.4.4 Others
1.5 Global Human Prothrombin Complex 麻豆原创 Size & Forecast
1.5.1 Global Human Prothrombin Complex Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Human Prothrombin Complex Sales Quantity (2020-2031)
1.5.3 Global Human Prothrombin Complex Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Takeda
2.1.1 Takeda Details
2.1.2 Takeda Major Business
2.1.3 Takeda Human Prothrombin Complex Product and Services
2.1.4 Takeda Human Prothrombin Complex Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Takeda Recent Developments/Updates
2.2 CSL
2.2.1 CSL Details
2.2.2 CSL Major Business
2.2.3 CSL Human Prothrombin Complex Product and Services
2.2.4 CSL Human Prothrombin Complex Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 CSL Recent Developments/Updates
2.3 Grifols
2.3.1 Grifols Details
2.3.2 Grifols Major Business
2.3.3 Grifols Human Prothrombin Complex Product and Services
2.3.4 Grifols Human Prothrombin Complex Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Grifols Recent Developments/Updates
2.4 Octapharma
2.4.1 Octapharma Details
2.4.2 Octapharma Major Business
2.4.3 Octapharma Human Prothrombin Complex Product and Services
2.4.4 Octapharma Human Prothrombin Complex Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Octapharma Recent Developments/Updates
2.5 Hualan Biological
2.5.1 Hualan Biological Details
2.5.2 Hualan Biological Major Business
2.5.3 Hualan Biological Human Prothrombin Complex Product and Services
2.5.4 Hualan Biological Human Prothrombin Complex Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Hualan Biological Recent Developments/Updates
2.6 Meheco Xinxing Pharma
2.6.1 Meheco Xinxing Pharma Details
2.6.2 Meheco Xinxing Pharma Major Business
2.6.3 Meheco Xinxing Pharma Human Prothrombin Complex Product and Services
2.6.4 Meheco Xinxing Pharma Human Prothrombin Complex Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Meheco Xinxing Pharma Recent Developments/Updates
3 Competitive Environment: Human Prothrombin Complex by Manufacturer
3.1 Global Human Prothrombin Complex Sales Quantity by Manufacturer (2020-2025)
3.2 Global Human Prothrombin Complex Revenue by Manufacturer (2020-2025)
3.3 Global Human Prothrombin Complex Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Human Prothrombin Complex by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Human Prothrombin Complex Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Human Prothrombin Complex Manufacturer 麻豆原创 Share in 2024
3.5 Human Prothrombin Complex 麻豆原创: Overall Company Footprint Analysis
3.5.1 Human Prothrombin Complex 麻豆原创: Region Footprint
3.5.2 Human Prothrombin Complex 麻豆原创: Company Product Type Footprint
3.5.3 Human Prothrombin Complex 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Human Prothrombin Complex 麻豆原创 Size by Region
4.1.1 Global Human Prothrombin Complex Sales Quantity by Region (2020-2031)
4.1.2 Global Human Prothrombin Complex Consumption Value by Region (2020-2031)
4.1.3 Global Human Prothrombin Complex Average Price by Region (2020-2031)
4.2 North America Human Prothrombin Complex Consumption Value (2020-2031)
4.3 Europe Human Prothrombin Complex Consumption Value (2020-2031)
4.4 Asia-Pacific Human Prothrombin Complex Consumption Value (2020-2031)
4.5 South America Human Prothrombin Complex Consumption Value (2020-2031)
4.6 Middle East & Africa Human Prothrombin Complex Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Human Prothrombin Complex Sales Quantity by Type (2020-2031)
5.2 Global Human Prothrombin Complex Consumption Value by Type (2020-2031)
5.3 Global Human Prothrombin Complex Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Human Prothrombin Complex Sales Quantity by Application (2020-2031)
6.2 Global Human Prothrombin Complex Consumption Value by Application (2020-2031)
6.3 Global Human Prothrombin Complex Average Price by Application (2020-2031)
7 North America
7.1 North America Human Prothrombin Complex Sales Quantity by Type (2020-2031)
7.2 North America Human Prothrombin Complex Sales Quantity by Application (2020-2031)
7.3 North America Human Prothrombin Complex 麻豆原创 Size by Country
7.3.1 North America Human Prothrombin Complex Sales Quantity by Country (2020-2031)
7.3.2 North America Human Prothrombin Complex Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Human Prothrombin Complex Sales Quantity by Type (2020-2031)
8.2 Europe Human Prothrombin Complex Sales Quantity by Application (2020-2031)
8.3 Europe Human Prothrombin Complex 麻豆原创 Size by Country
8.3.1 Europe Human Prothrombin Complex Sales Quantity by Country (2020-2031)
8.3.2 Europe Human Prothrombin Complex Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Human Prothrombin Complex Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Human Prothrombin Complex Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Human Prothrombin Complex 麻豆原创 Size by Region
9.3.1 Asia-Pacific Human Prothrombin Complex Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Human Prothrombin Complex Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Human Prothrombin Complex Sales Quantity by Type (2020-2031)
10.2 South America Human Prothrombin Complex Sales Quantity by Application (2020-2031)
10.3 South America Human Prothrombin Complex 麻豆原创 Size by Country
10.3.1 South America Human Prothrombin Complex Sales Quantity by Country (2020-2031)
10.3.2 South America Human Prothrombin Complex Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Human Prothrombin Complex Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Human Prothrombin Complex Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Human Prothrombin Complex 麻豆原创 Size by Country
11.3.1 Middle East & Africa Human Prothrombin Complex Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Human Prothrombin Complex Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Human Prothrombin Complex 麻豆原创 Drivers
12.2 Human Prothrombin Complex 麻豆原创 Restraints
12.3 Human Prothrombin Complex Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Human Prothrombin Complex and Key Manufacturers
13.2 Manufacturing Costs Percentage of Human Prothrombin Complex
13.3 Human Prothrombin Complex Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Human Prothrombin Complex Typical Distributors
14.3 Human Prothrombin Complex Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Takeda
CSL
Grifols
Octapharma
Hualan Biological
Meheco Xinxing Pharma
听
听
*If Applicable.
